FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesLeadership Lessons for Re-Entry
Topics: Leadership, Management
Webinar
Free
EAP 104: EAP Communication and Stakeholder Management
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Presentation
Members
Recent Developments in the Global Regulatory Landscape
Topic: Regulatory
Webinar
Free
